Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FREQ
- Price
- -
- Stock movement up
- +0.84 (5.94%)
- Company name
- Frequency Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 547.08M
- Ent value
- 514.97M
- Price/Sales
- -
- Price/Book
- 14.89
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -85.24%
- 3 year return
- -75.79%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
FREQ does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | 26.96 |
| Price to EBITDA | 15.31 |
| EV to EBITDA | 14.41 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 14.89 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 36.52M |
| EPS (TTM) | -1.61 |
| FCF per share (TTM) | 0.55 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -63.20M |
| Net income (TTM) | -59.31M |
| EPS (TTM) | -1.61 |
| EPS (1y forward) | -1.14 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 41.72M |
| Net receivables | 0.00 |
| Total current assets | 42.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 46.35M |
| Accounts payable | 338.00K |
| Short/Current long term debt | 1.43M |
| Total current liabilities | 9.61M |
| Total liabilities | 9.61M |
| Shareholder's equity | 36.74M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -37.78M |
| Capital expenditures (TTM) | 116.00K |
| Free cash flow (TTM) | 20.30M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -161.46% |
| Return on Assets | -127.97% |
| Return on Invested Capital | -155.42% |
| Cash Return on Invested Capital | 53.18% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| FREQ | S&P500 | |
| Current price drop from All-time high | -99.46% | -9.01% |
| Highest price drop | -99.61% | -56.47% |
| Date of highest drop | 30 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -66.24% | -11.07% |
| Avg time to new high | 26 days | 12 days |
| Max time to new high | 683 days | 1805 days |
COMPANY DETAILS
Marketcap
547.08M
Marketcap category
Small-cap
Description
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Employees
46
Website
Investor relations
-
SEC filings
CEO
David L. Lucchino
Country
USA
City
Woburn
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner